| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3789 |
| Trial ID | NCT06297226 |
| Disease | Multiple Myeloma |
| Altered gene | GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BMS-986393 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) |
| Year | 2024 |
| Country | Canada|Japan|United States |
| Company sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Other ID(s) | CA088-1000 |
| Cohort 1 | |||||||
|
|||||||